Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Benefit of cancer prevention surgery differs between women with BRCA1 and BRCA2 mutations

12.02.2008
The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers. All previous studies evaluating this approach have only examined BRCA1 and BRCA2 mutation carriers together or have limited their analysis to BRCA1 mutation carriers alone.

The findings of the new study, to be published in the March 2008 issue of the Journal of Clinical Oncology, may have important implications for women comparing the risks and benefits of specific cancer-risk-reduction options.

According to the research, the surgery – called risk-reducing salpingo-oophorectomy (RRSO) – may confer different benefits for women at inherited risk for breast and ovarian cancer depending upon whether BRCA1 or BRCA2 is abnormal. The efficacy of this procedure for the prevention of breast and gynecologic cancer had never been evaluated in groups of women stratified according to mutation type, despite 17 percent to 39 percent of all BRCA mutation carriers having a mutation in the BRCA2 gene.

“These findings will allow doctors to better tailor risk-reduction approaches for women at inherited risk for breast and ovarian cancer,” said the study’s lead author, Noah Kauff, MD, a gynecologist and geneticist at MSKCC. “Given these results, further studies evaluating the efficacy of risk-reduction strategies in BRCA mutation carriers will likely need to stratify by the specific gene mutated,” he added.

Researchers compared the incidence of breast and gynecologic cancers between a group of 509 women 30 years of age or older who carried a BRCA1 or BRCA2 mutation and had undergone RRSO, and a group of 283 women with these mutations who did not have the surgery. The women were followed prospectively for three years via questionnaire and medical record review.

Investigators found that RRSO was associated with a 72 percent breast cancer risk reduction in women with BRCA2 mutations – nearly twice the reduction in breast cancer risk compared to women with BRCA1 mutations. The surgery also reduced the risk of gynecologic cancer by 85 percent in women with a BRCA1 mutation. While protection against gynecologic cancer was suggested in women with a BRCA2 mutation, researchers were not able to estimate the level of reduced risk due to the low incidence of gynecologic cancers among women with these mutations.

Further analyses demonstrated that RRSO appeared to reduce the risk of estrogen receptor (ER)-positive breast cancer by 78 percent in women with a mutation in either BRCA1 or BRCA2, but had no effect on the development of ER-negative breast cancers. Because BRCA1 carriers are more likely to be diagnosed with ER-negative breast cancers, the authors note that carriers of these mutations need to consider additional breast-cancer-risk-reduction strategies, such as intensive screening with breast MRI or prophylactic mastectomy.

“While our results suggest that removal of the ovaries in women with BRCA1 or BRCA2 mutations is highly protective against ER-positive breast cancers, further research is urgently needed to develop effective non-surgical prevention strategies for the ER-negative cancers that are frequently associated with these mutations,” said Dr. Kauff.

Esther Napolitano | EurekAlert!
Further information:
http://www.mskcc.org

Further reports about: BRCA1 BRCA2 Gynecologic Mutation Prevention RRSO breast cancer carriers

More articles from Life Sciences:

nachricht What the world's tiniest 'monster truck' reveals
23.08.2017 | American Chemical Society

nachricht Treating arthritis with algae
23.08.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Researchers devise microreactor to study formation of methane hydrate

23.08.2017 | Materials Sciences

ShAPEing the future of magnesium car parts

23.08.2017 | Automotive Engineering

New insights into the world of trypanosomes

23.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>